Point72 Asset Management’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.02M Sell
32,200
-126,700
-80% -$10.1M ﹤0.01% 2295
2025
Q4
$15.2M Buy
+158,900
New +$15.6M 0.02% 1089
2025
Q3
Sell
-3,100
Closed -$333K 2334
2025
Q2
$333K Buy
3,100
+1,800
+138% +$182K ﹤0.01% 1893
2025
Q1
$131K Sell
1,300
-21,600
-94% -$2.18M ﹤0.01% 1887
2024
Q4
$2.05M Sell
22,900
-65,200
-74% -$5.74M ﹤0.01% 1236
2024
Q3
$7.38M Buy
88,100
+68,400
+347% +$5.39M 0.02% 761
2024
Q2
$1.52M Sell
19,700
-69,100
-78% -$5.06M ﹤0.01% 1170
2024
Q1
$6.08M Sell
88,800
-130,100
-59% -$8.37M 0.01% 902
2023
Q4
$12.7M Hold
218,900
0.03% 609
2023
Q3
$11.6M Buy
218,900
+199,200
+1,011% +$10.4M 0.03% 595
2023
Q2
$1.07M Buy
+19,700
New +$1.03M ﹤0.01% 1127
2023
Q1
Sell
-19,800
Closed -$916K 2250
2022
Q4
$916K Hold
19,800
﹤0.01% 1064
2022
Q3
$767K Sell
19,800
-1,600
-7% -$64.2K ﹤0.01% 1103
2022
Q2
$798K Buy
+21,400
New +$871K ﹤0.01% 1123

Other funds holding BSX

Point72 Asset Management's BSX Position: Q1 2026 in Review

Point72 Asset Management increased its Boston Scientific (BSX) stake by 51% in Q1 2026, buying an estimated $100M and bringing the position to 3,687,315 shares worth $231M. The position accounts for 0.3% of the portfolio, ranked #41.

Point72 Asset Management first reported a position in BSX in Q3 2014 and has held it in 40 quarters since. The position peaked at $339M in Q3 2023. 1,664 funds tracked by Wall St. Rank hold BSX as of Q1 2026.

  • Point72 Asset Management held 3,687,315 shares of Boston Scientific worth $231M as of Q1 2026.
  • Point72 Asset Management bought 1,252,752 Boston Scientific shares in Q1 2026, an estimated $100M.
  • Boston Scientific made up 0.3% of Point72 Asset Management's portfolio in Q1 2026, its #41 holding.
  • Point72 Asset Management first reported a position in Boston Scientific in Q3 2014 and has held it in 40 quarters since.
  • Point72 Asset Management's Boston Scientific position peaked at $339M in Q3 2023.
  • 1,664 funds tracked by Wall St. Rank held Boston Scientific as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.